23135-50-4

Basic information

• Product Name: 5-(CARBOBENZOXYAMINO)VALERIC ACID
• Synonyms: 5-BENZYLOXYCARBONYLAMINO-PENTANOIC ACID;5-(CARBOBENZOXYAMINO)VALERIC ACID, 98+%(T);5-(Carbobenzoxyamino)pentanoic Acid N-Cbz-5-aminovaleric Acid N-Cbz-5-aminopentanoic Acid;delta-Carbobenzoxyaminovaleric acid;N-[(Benzyloxy)carbonyl]-5-aminopentanoic acid;Z-5-Ava-OH;5-(Benzyloxycarbonylamino)valeric acid;5-[[(phenylmethoxy)carbonyl]amino]- Pentanoic acid
• CAS NO: 23135-50-4
• Molecular Formula: C₁₃H₁₇NO₄
• Molecular Weight: 251.27838
• Mol File: 23135-50-4.mol

Chemical Properties

• Melting Point: 106 °C
• Boiling Point: 459.9ºC at 760 mmHg
• Flash Point: 231.9ºC
• Appearance: Off-white/Solid
• Density: 1.186g/cm3
• Vapor Pressure: 2.97E-09mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.72±0.10(Predicted)
• CAS DataBase Reference: 5-(CARBOBENZOXYAMINO)VALERIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(CARBOBENZOXYAMINO)VALERIC ACID(23135-50-4)
• EPA Substance Registry System: 5-(CARBOBENZOXYAMINO)VALERIC ACID(23135-50-4)

Safety Data

• Hazardous Substances Data: 23135-50-4(Hazardous Substances Data)

Usage

Uses

Used in Peptide and Protein Synthesis:
5-(Carbobenzoxyamino)valeric acid is utilized as a protecting reagent for the amino group during the synthesis of peptides and proteins. The Cbz group shields the amino group from unwanted reactions, allowing for selective and controlled peptide bond formation, which is crucial for the successful synthesis of complex peptide and protein structures.
Used in Drug Development:
Due to its potential applications in drug development, 5-(Carbobenzoxyamino)valeric acid serves as a valuable component in the design and synthesis of novel pharmaceutical compounds. Its reactivity and functional group compatibility enable the creation of diverse drug candidates with potential therapeutic benefits.
Used in Medical Research:
In the field of medical research, 5-(Carbobenzoxyamino)valeric acid is employed as a building block for the preparation of various pharmaceutical compounds. Its unique properties and reactivity contribute to the development of innovative therapeutic agents and diagnostic tools, furthering our understanding of disease mechanisms and treatment strategies.
Used in Organic Chemistry:
As a versatile reagent in organic chemistry, 5-(Carbobenzoxyamino)valeric acid is involved in a wide range of chemical reactions and processes. Its functional group compatibility allows for the synthesis of diverse organic compounds, contributing to the advancement of chemical research and the development of new materials and applications.
Used in Biochemistry:
In biochemistry, 5-(Carbobenzoxyamino)valeric acid plays a critical role as an intermediate in the synthesis of biologically active molecules. Its ability to protect the amino group and participate in various chemical transformations makes it an essential component in the preparation of bioactive compounds for research and therapeutic applications.

InChI:InChI=1/C13H17NO4/c15-12(16)8-4-5-9-14-13(17)18-10-11-6-2-1-3-7-11/h1-3,6-7H,4-5,8-10H2,(H,14,17)(H,15,16)

Upstream product

• 501-53-1 benzyl chloroformate 
• 660-88-8 5-aminopentanoic acid 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 
• 627-95-2 5-amino-valeric acid ; hydrochloride 

Downstream Products

• 19832-04-3 2-(piperidin-2-yl)acetic acid 
• 115012-31-2 Z-δ-Ava-NH-Phenyl 
• 76944-94-0 N-benzyloxycarbonyl-5-aminovaleric acid succinimide ester 
• 125174-08-5 N,N-bis(2-hydroxyethyl)-4-<5-pentanamido>aniline 
• 112078-59-8 (2S,5R,6R)-1-aza-3,3'-dimethyl-6-(5-N-benzyloxycarbonylaminopentanamido)-7-oxo-4-thiabicyclo<3.2.0>heptane-2-carboxylic acid p-nitrobenzyl ester 
• 99017-64-8 ethyl 7-<(benzyloxycarbonyl)amino>-3-oxoheptanoate 
• 121838-39-9 Z-Apn-Trp-OMe 
• 114226-49-2 N-<2-O-<2-acetamido-1,5-anhydro-6-O-(5-benzyloxycarbonylaminopentanoyl)-2,3-dideoxy-D-glucitol-3-yl>-D-lactoyl>-L-alanyl-D-isoglutamine methyl ester 
• 216502-73-7 (4-Chlorocarbonyl-butyl)-carbamic acid benzyl ester 
• 90819-27-5 benzyl (5-oxo-5-(phenethylamino)pentyl)carbamate 
• 76523-70-1 Z-5-Ava-Pro-Gly-OEt 
• 63983-88-0 tert-butyl 5-{[(benzyloxy)carbonyl]amino}pentanoate 
• 106651-46-1 N-carbobenzoxy(δ-aminovaleryl)-L-phenylalanine amide 
• 118970-67-5 3-[4-[4-[5-(Benzyloxycarbonylamino)pentanoamido]-1-methylpyrrole-2-carbonylamino]-1-methylpyrrole-2-carbonylamino]dimethylaminopropane 

Relevant articles and documents

SUBSTITUTED 2,3-BENZODIAZEPINES DERIVATIVES

Derivatives of 2,3- benzodiazepines as inhibitors of Bromodomain and extra C-terminal domain (BET) proteins, in particular the BRD4 family member, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceuti

Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo

The antioxidant natural product sulforaphane (SFN) is an oil with poor aqueous and thermal stability. Recent work with SFN has sought to optimize methods of formulation for oral and topical administration. Herein we report the design of new analogs of SFN with the goal of improving stability and drug-like properties. Lead compounds were selected based on potency in a cellular screen and physicochemical properties. Among these, 12 had good aqueous solubility, permeability and long-term solid-state stability at 23 °C. Compound 12 also displayed comparable or better efficacy in cellular assays relative to SFN and had in vivo activity in a mouse cigarette smoke challenge model of acute oxidative stress.

NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION

The present invention provides novel compounds having general formula (I), wherein R1 to R4, A, W, Q and Y are as described herein, compositions including the compounds and methods of using the compounds.

Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate

Epidermal growth factor receptor inhibitors (EGFR-TKIs) represent a class of compounds widely used in anticancer therapy. An increasing number of studies reports on combination therapies in which the block of the EGFR-TK activity is associated with inhibition of its downstream pathways, as PI3K-Akt. Sulforaphane targets the PI3K-Akt pathway whose dysregulation is implicated in many functions of cancer cells. According to these considerations, a series of multitarget molecules have been designed by combining key structural features derived from an EGFR-TKI, PD168393, and the isothiocyanate sulforaphane. Among the obtained molecules 1-6, compound 6 emerges as a promising lead compound able to exert antiproliferative and proapoptotic effects in A431 epithelial cancer cell line by covalently binding to EGFR-TK, and reducing the phosphorylation of Akt without affecting the total Akt levels.

Inhibitors interacting with the magnesium binding site of reverse transcriptase: Synthesis and biological activity studies of 3′-(Ω- amino-acyl) amino-3′-deoxy-thymidine

Active site of reverse transcriptase contains carboxylate groups involved in the magnesium binding. We prepared some nucleoside analogs which could bind to these carboxylates preventing the binding of nucleotides. To the 3′-amino-3′-deoxy-thymidine, different N-protected ω-amino-acids were bound, the protection removed to give the 3′-(ω-amino-acyl-) amino-3′-deoxy-thymidines in good yield. Some showed moderate to low activity in HIV 1 replication test. Copyright Taylor & Francis Group, LLC.

Synthesis and self-association properties of flexible guanidiniocarbonylpyrrole-carboxylate zwitterions in DMSO: Intra- versus intermolecular ion pairing

(Chemical Equation Presented) We have synthesized a new class of flexible zwitterions 6a-e, in which a carboxylate is linked via an alkyl chain with variable length (one to five methylene groups) to a guanidiniocarbonylpyrrole cation. The self-association properties of these zwitterions were determined by NMR dilution studies in DMSO and by ESI-MS experiments. The stability and hence also the size of the aggregates formed via self-assembly is critically dependent on the length and therefore flexibility of the spacer. Whereas the smallest zwitterion 6a forms large aggregates already at low concentrations, the more flexible zwitterions only form small oligomers (6b) or dimers (6c-e) at much larger concentrations. The differences between the five zwitterions can be explained based on the different extent of intramolecular ion pairing within the monomers. Any intramolecular ion pairing, which becomes possible with increasing linker length, stabilizes the monomer and therefore destabilizes any oligomer.

Phospholipid prodrugs of anti-proliferative drugs

The invention discloses prodrugs comprising anti-proliferative drugs covalently linked, via bridging group, to a phospholipid moiety such that the active species is preferentially released, preferably by enzymatic cleavage, at the required site of action. The invention further discloses pharmaceutical compositions said prodrugs and the uses thereof for the treatment of diseases and disorders related to inflammatory, to degenerative or atrophic conditions, and to uncontrolled cell growth. FIG.1depicts a graph of animal survival during the course of an experiment wherein mice were i.p. transplanted with 11210 mouse leukemia cells and then treated with vehicle only (squares), MTX (triangles) or molar equivalent dose of DP-MTX071 (circles) according to the regiment described example in Example 11.

PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions.

Reagents and methods for specific binding assays

The present invention relates to compounds that are bis-biotins. These compounds comprise two biotinyl radicals connected by a chain of atoms, usually at least 16 atoms in length. The bis-biotin is conjugated to a member of a specific binding pair ("sbp m

The Preference Profile in Ruthenium Tetroxide Oxidations

The preference profile of RuVIII-generated in a catalytic cycle, maintained by periodate in carbon tetrachloride : acetonitrile : water -has been examined from a practical vantage using tyrosine, phenylalanine and lysine as primary substrates. Other factors such as pH, acetonitrile versatility, transport of oxidized ruthenium species across the layers and hydrophobic alignment, influence the course of the reaction. Aryl oxidation, which takes place at the organic interface, is strongly influenced by ring perturbation (pOH-C6H4CH2CH,++; PhCH2CH,+, PhCH2O,+; PhCH2OCONH(Z),-; PhCH2OCO,-; pOH-C6H4CH2CO,+; PhCH2CO,-; PhCO,-). In the case of tyrosine, the preference profile switches from ring oxidation at pH 3 to α-amino group oxidation at pH 6 and 9, whilst with phenylalanine, the amino group is exclusively oxidized even at pH 3. With lysine, the reasonable differences in pKa between the α-amino group (8.95) and the ω-amino unit (10.53), elicit sharp preferences. At pH 3 as well as at 6, the α-amino group is selectively oxidized leading to glutaric acid mono-amide, a finding supported by studies with Nα and Nω protected lysines. Lysine and arginine side-chains are found largely unaffected by the reagent at pH 3 and 6. The findings have been rationalized on the basis of an integrated mechanism. The work has endeavoured to reconcile seemingly conflicting reports in the literature and to project the reagent for selective modifications in synthesis.